| Diabetes Mellitus, Non-Insulin-Dependent
Soliqua vs Tradjenta
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Soliqua 100/33 vs Tradjenta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTradjenta has a higher rate of injection site reactions vs Soliqua 100/33 based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tradjenta but not Soliqua 100/33, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Soliqua 100/33
Tradjenta
At A Glance
SC injection
Once daily
Basal insulin + GLP-1 receptor agonist
Oral
Daily
DPP-4 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent 15 units SC once daily for patients naive to basal insulin or GLP-1 receptor agonist, on a GLP-1 receptor agonist, or on <30 units basal insulin daily; 30 units SC once daily for patients on 30-60 units basal insulin daily; titrate by 2-4 units weekly; max 60 units (60 units insulin glargine/20 mcg lixisenatide) daily; inject within 1 hour prior to first meal of the day.
Diabetes Mellitus, Non-Insulin-Dependent 5 mg orally once daily, with or without food.
Contraindications
- Hypoglycemia episodes
- Serious hypersensitivity to insulin glargine, lixisenatide, or any excipient in SOLIQUA 100/33
- Hypersensitivity to linagliptin or any excipient in TRADJENTA, including reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity
Adverse Reactions
Most common (>=5%) Nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache, hypoglycemia
Serious Anaphylaxis, serious hypersensitivity, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, hypokalemia, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Localized cutaneous amyloidosis (insulin glargine); acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, dysgeusia, dysesthesia, pulmonary aspiration, acute renal failure, alopecia (lixisenatide)
Most common (>=2%) Nasopharyngitis, diarrhea, cough
Serious Pancreatitis, hypoglycemia with concomitant insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid, rash
Pharmacology
SOLIQUA 100/33 combines insulin glargine, a basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, with lixisenatide, a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
DPP-4 inhibitor; linagliptin reversibly inhibits DPP-4, the enzyme that degrades incretin hormones GLP-1 and GIP, thereby increasing active incretin concentrations, stimulating glucose-dependent insulin release from pancreatic beta cells, and reducing glucagon secretion from pancreatic alpha-cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Soliqua 100/33
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (7/12) · Qty limit (11/12)
Tradjenta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Soliqua 100/33
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Tradjenta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Soliqua 100/33
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Tradjenta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Soliqua 100/33.
No savings programs available for Tradjenta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Soliqua 100/33View full Soliqua 100/33 profile
TradjentaView full Tradjenta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.